Feasibility Trial of a Culturally Tailored Resilience Intervention for Underserved Breast Cancer Survivors
NCT07930715, Not applicable, Not yet recruiting, University College Dublin
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Feasibility Trial of a Culturally Tailored Resilience Intervention for Underserved Breast Cancer Survivors | ClinicalTrials.gov |
| NCT number | NCT07930715 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 80 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | University College Dublin | ClinicalTrials.gov |
| Conditions | Breast Cancer, Cancer Survivorship | ClinicalTrials.gov |
| Interventions | BRIGHT Resilience Intervention, BRIGHT Survivorship Resource Booklet | ClinicalTrials.gov |
| First posted | 2026-11-12 | ClinicalTrials.gov |
| Last updated | 2026-11-12 | ClinicalTrials.gov |
Registered outcomes 11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Recruitment Rate | From start to end of recruitment, up to 6 months | Number of participants randomised per site per month. Progression target: at least 4 participants per site per month. | ClinicalTrials.gov |
| Primary | Retention | 3 months after the end of the intervention | Percentage of randomised participants who complete the 3-month follow-up questionnaires. Progression target: at least 80%. | ClinicalTrials.gov |
| Primary | Session Attendance | During the 8-week intervention | Percentage of the 8 intervention sessions attended by participants in the BRIGHT arm, from attendance records. Progression target: at least 75% session completion. | ClinicalTrials.gov |
| Primary | Intervention Fidelity | During the 8-week intervention | Percentage of planned session components delivered as intended, assessed using facilitator session checklists and independent review of a sample of recorded sessions. Progression target: at least 85%. | ClinicalTrials.gov |
| Primary | Acceptability | Week 8 (end of the intervention) | Participant satisfaction with the intervention, measured using a questionnaire based on the Theoretical Framework of Acceptability, and explored in interviews with 15 to 20 participants and facilitators. | ClinicalTrials.gov |
| Secondary | Depressive Symptoms | Baseline, Week 8 and 3 months after the end of the intervention | Patient Health Questionnaire-9 (PHQ-9). Scores range from 0 to 27; higher scores mean more severe depressive symptoms. | ClinicalTrials.gov |
| Secondary | Anxiety Symptoms | Baseline, Week 8 and 3 months after the end of the intervention | Generalised Anxiety Disorder-7 (GAD-7). Scores range from 0 to 21; higher scores mean more severe anxiety. | ClinicalTrials.gov |
| Secondary | Fear of Cancer Recurrence | Baseline, Week 8 and 3 months after the end of the intervention | Fear of Cancer Recurrence Inventory, Short Form (FCRI-SF). Scores range from 0 to 36; higher scores mean greater fear of recurrence. | ClinicalTrials.gov |
| Secondary | Cancer-Specific Quality of Life | Baseline, Week 8 and 3 months after the end of the intervention | Functional Assessment of Cancer Therapy, Breast (FACT-B). Total scores range from 0 to 148; higher scores mean better quality of life. | ClinicalTrials.gov |
| Secondary | Psychological Resilience | Baseline, Week 8 and 3 months after the end of the intervention | Connor-Davidson Resilience Scale (CD-RISC). Higher scores mean greater resilience | ClinicalTrials.gov |
| Secondary | Unmet Supportive Care Needs | Baseline, Week 8 and 3 months after the end of the intervention | Supportive Care Needs Survey, Short Form (SCNS-SF34). Domain scores range from 0 to 100; higher scores mean greater unmet need. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.3.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 4a570df2e7274cee2d4fa2959402fab41880e2cd412e4b590390035fbea69391 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
Release trials-2026-11-12-0.3.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.